Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738738 | 1.00 | LMNA (0.37) | LMNAHTR1ADRD2DRD4PTGDR2 | |
| SCHEMBL14738909 | 0.87 | PTGDR2 (0.39) | LMNAHTR1ADRD2DRD4PTGDR2 | |
| SCHEMBL14753487 | 0.85 | FAAH (0.35) | LMNACNR1FAAHALDH1A1 | |
| SCHEMBL14739273 | 0.85 | FAAH (0.35) | LMNACNR1FAAHALDH1A1 | |
| SCHEMBL7716091 | 0.85 | FAAH (0.35) | LMNACNR1FAAHALDH1A1 | |
| SCHEMBL14739777 | 0.85 | FAAH (0.35) | LMNACNR1FAAHALDH1A1 | |
| SCHEMBL7711534 | 0.84 | P2RX3 (0.38) | LMNAHTR1ADRD2DRD4PTGDR2 | |
| SCHEMBL7713646 | 0.80 | CNR1 (0.50) | LMNACNR1CNR2 | |
| SCHEMBL7713726 | 0.76 | FAAH (0.47) | LMNAHTR1ADRD2DRD4PTGDR2 | |
| SCHEMBL14739457 | 0.69 | TP53 (0.35) | HTR1ADRD2DRD4PTGDR2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | claimed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059850-A1 | AZA-INDOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH | FAAH, FAAH2, IDO1 | LMNA 3097/4885HTR1A 59/4885DRD2 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.